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Abstract
Background: Pharmaceutical drug poisonings have previously been reported using single sources
of information, either hospital data or forensic data, which might not reveal the true incidence. We
therefore aimed to estimate the incidence of suspected fatal drug poisonings, defined as poisonings
by pharmaceutical agents, by using all relevant case records from various sources in a Swedish
population.
Methods: Every seventh randomly selected deceased in three counties in southeastern Sweden
during a one-year period was identified in the Cause of Death Register. Relevant case records
(death certificates, files from hospitals and/or primary care centres and medico-legal files) were
reviewed for all study subjects.
Results:  Of 1574 deceased study subjects, 12 cases were classified as pharmaceutical drug
poisonings according to the death certificates and 10 according to the medico-legal files. When
reviewing all available data sources, 9 subjects (0.57%; 95% confidence interval: 0.20–0.94%) were
classified as drug poisonings, corresponding to an incidence of 6.5 (95% confidence interval: 2.3–
10.7) per 100 000 person-years in the general population. The drug groups most often implicated
were benzodiazepines (33%), antihistamines (33%) and analgesics (22%).
Conclusion: Fatal drug poisonings is a relatively common cause of death in Sweden. By using
multiple sources of information when investigating the proportion of fatal poisonings in a
population, more accurate estimates may be obtained.
Background
Drug poisonings, by pharmaceutical agents, have been
reported to comprise approximately 1% of emergency
department visits [1-3] and up to 0.4% of these result in a
fatal outcome [1,3]. Among the deceased subjected to a
forensic autopsy, 0.2% of the deaths have been reported
to be caused by pharmaceutical drug poisonings [4]. The
incidence of fatal pharmaceutical drug poisonings in a
general population has previously been estimated to vary
between 0.14 and 5.3 per 100 000 inhabitants based on
data from single sources of information, such as hospital
data [5,6] or forensic data [4,7-9]. The incidence of fatal
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drug poisonings in a general population has previously
been estimated based on the official cause of death statis-
tics [10-12]. However, in these compilations, pharmaceu-
tical drug poisonings were not analysed separately. Since
it can be expected that not all cases of fatal drug poison-
ings will be identified by using one single data source,
these studies might not be able to reveal the true inci-
dence. We therefore aimed to estimate the incidence of
suspected fatal drug poisonings, defined as poisonings by
pharmaceutical agents, by using all relevant case records
from various sources in a Swedish population. Another
purpose of the study was to estimate the number of cases
reported by the different types of case records included.
Methods
This was a retrospective study conducted in three counties
in southeastern Sweden – Östergötland, Jönköping and
Kalmar counties – comprising a mean population of 974
884 inhabitants during the study period, 1 January 2001
to 31 December 2001. Approval of this study was
obtained from the Swedish National Board of Health and
Welfare. All 11 015 fatalities in the area were identified
according to their annual report; Causes of Death 2001
[13]. One out of every seventh deceased in the population
was selected at random and the death certificates were
retrieved. Since all Swedish residents receive a unique per-
sonal identification number, it is possible to link the
information from the death certificates to other case
records. The data extraction procedure has previously
been described in detail elsewhere [14]. In short, a thor-
ough drug history for all 1574 subjects focusing particu-
larly on the 14 days preceding death was obtained from
relevant case records (medical charts from hospitals and/
or primary care centres, death certificates and medico-
legal files). During this first examination, performed by
four health care professionals, relevant information was
extracted to a standardised form. Further evaluation of
possible fatal poisonings and their causality was per-
formed by two pharmacists, two clinical pharmacologists
and a forensic pathologist in accordance with WHO crite-
ria [15]. A case was categorised as drug poisoning if there
was a relationship between death and drug toxicity which
was assessed as at least possible  (known toxicity of the
drug(s) suspected and reasonable time between intake
and death but other contributory causes of death may
exist). For an event to be classified as a drug poisoning,
consensus had to be reached between all assessors.
Drug poisonings were defined as poisonings by pharma-
ceutical agents, and were categorised as being intentional,
unintentional or with unknown intent. More than one
drug could have been involved in the poisoning of a sin-
gle case. In fatalities where a forensic autopsy investiga-
tion had been performed (in unnatural deaths and
suspected unnatural deaths as a part of the post-mortem
investigation), femoral blood, urine and vitreous samples
were collected and screened for drugs and ethanol. In sub-
jects in whom drugs were detected, compilations of fatal
and non-fatal concentrations of drugs in post-mortem
femoral blood was used to support the causality assess-
ment [16,17] in addition to the perusal of the history and
the description of the circumstances surrounding death in
each case. To control for possible misclassification from
the first assessment, we reviewed every tenth of the fatali-
ties not categorised as drug poisonings.
Statistical analyses were performed using the statistical
program package STATA (STATA/IC 10.0 for Windows;
Statacorp, TX, US). The analyses included Fischer exact
tests for dichotomous variables and Mann-Whitney tests
for continuous variables. P-values < 0.05 were considered
statistically significant.
Results
The death certificates were retrieved for all 1574 subjects
and in 99% of the total study population (1553 subjects),
information about drug prescriptions during the last year
before death could be retrieved. Medical case records were
available for 1503 subjects (95%) and forensic autopsies
were carried out in 83 subjects (5.3%), and medico-legal
files were available in all of these subjects. Based on the
information from the death certificates, 12 fatalities of the
1574 deceased study subjects were classified as pharma-
ceutical drug poisonings. Based on the information from
the medico-legal files, 10 fatalities were classified as phar-
maceutical drug poisonings. When reviewing all available
data sources, 9 subjects (0.57%; 95% confidence interval:
0.20–0.94%) were classified as drug poisonings, corre-
sponding to an incidence of 6.5 (95% confidence interval:
2.3–10.7) per 100 000 person-years in the general popu-
lation. The characteristics of the study population are
shown in Table 1. The drug groups most often implicated
were benzodiazepines (33%), antihistamines (33%) and
analgesics (22%) (Table 2). Of the 9 poisonings, 4 could
be classified as intentional, 3 as unintentional, and 2 as
having unknown intent. When reviewing every tenth of
the 1565 fatalities not classified as drug poisonings, no
additional fatal drug poisonings were identified.
Discussion
In the present study, which identified subjects by means
of a review of death certificates as well as medical charts
from hospital and/or ambulatory care and medico-legal
files, 0.57% of the deaths were considered to be caused by
drug poisoning, corresponding to an incidence of 6.5 fatal
poisonings per 100 000 person-years. This proportion is
in accordance with the data in the Swedish forensic
pathology and toxicology databases, where about 550
fatal poisonings are registered annually (unpublished
observations). Given that Sweden has 9 million inhabit-BMC Clinical Pharmacology 2009, 9:7 http://www.biomedcentral.com/1472-6904/9/7
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ants, this figure corresponds to an incidence of 6.1 per 100
000 inhabitants. Published reports regarding the inci-
dence of fatal poisonings by a pharmaceutical agent in a
general population from other countries have been based
on either hospital data or medico-legal data. The inci-
dence of fatal drug poisonings has been estimated based
on hospital data to 0.35 per 100 000 person-years in Ice-
land [5] and 0.54 per 100 000 person-years in Finland [6].
From forensic data, the incidence of fatal drug poisonings
has been estimated to vary between 1.9 and 5.3 per 100
000 person-years in the US [7], 2.5 per 100 000 person-
years in Canada [8], 0.1 per 100 000 person-years in
Greece [4] and 2.0 per 100 000 person-years in New Zea-
land [9]. The variations observed may easily be explained
by regional differences, and the different kinds of data
sources used. The source of information used when stud-
ying fatal drug poisonings may not only influence the pro-
portion of cases observed in a population but also the
observed drugs suspected to have caused fatal poisonings
[18]. Hence, it is important to combine the information
from different data sources when investigating the propor-
tion of fatal poisonings in a population.
In Sweden, the information on the death certificates for all
fatalities are registered in the Cause of Death Register; in
our study, all the nine fatal drug poisonings as well as
three additional cases were reported as drug poisonings
on the death certificates. Therefore, the information on
the death certificates may be a valuable means to identify
fatal poisonings, although this approach is clearly
dependent on the quality of the examinations performed
to ascertain the cause(s) of death and the quality of the
ICD (International Classification of Diseases) coding on
the death certificates [19,20]. Moreover, to identify the
substances responsible for the poisonings, additional
information, e.g. from medical charts, is needed since the
ICD codes on the death certificates do not always specify
the individual substance(s) taken. Another pitfall when
Table 1: Characteristics of 1574 deceased subjects in a random sample of the Swedish population
Variable Subjects with pharmaceutical 
drug poisonings
(n = 9)
Remaining 
subjects
(n = 1565)
P value
Number of males (%) 5 (56%) 806 (51.5%) 1.0
Age, years, median (range)
Males 53 (26–85) 79 (0–101) 0.08
Females 49 (27–85) 84 (0–104) <0.05
Forensic autopsy performed, n (%) 7 (78%) 76 (4.9%) <0.01
Clinical autopsy performed, n (%) 0 (0%) 115 (7.3%) 1.0
Fatalities in hospital, n (%) 3 (33%) 636 (40.6%) 0.8
Table 2: Details of the 9 fatalities classified as pharmaceutical drug poisonings
Case number Sex Age Type of drug poisoning Suspected drugs Postmortem femoral
blood concentration
(μg/g)
1 Female 81 Intentional Nitrazepam NA
2 Female 34 Intentional Levomepromazine 3.6
3 Female 27 Intentional Morphine 0.18
4 Male 26 Intentional Nitrazepam 0.7a
+ carbamazepine 17
+ propoxyphene 1.2
+ promethazine 0.1
5M a l e b 85 Unintentional Digoxin NAc
6 Female 64 Unintentional Amitriptyline 3
7M a l e d 53 Unintentional Alimemazine 3.9
8 Male 80 Unknown intent Diazepam 0.4
9M a l e e 53 Unknown intent Alimemazine 0.7
Abbreviation: NA = not available
a Analysed as the metabolite 7-amino-nitrazepam
b This case was also suspected to have an adverse drug reaction contributing to the fatal outcome, a warfarin-related intravesical haemorrhage [14].
c The plasma concentration of digoxin was 6.9 mmol/l at admission to hospital.
d 1.5 ‰ of ethanol was detected in postmortem urine.
e 4.4 ‰ of ethanol was detected in postmortem femoral blood.BMC Clinical Pharmacology 2009, 9:7 http://www.biomedcentral.com/1472-6904/9/7
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using information on the death certificates only is that
several drugs may be mentioned without describing their
relative contribution to the poisoning.
Data registered based on forensic autopsies may be
another valuable source, since in Sweden most subjects
with suspected fatal poisonings are subjected to a forensic
autopsy, 78% of the cases in this study. In addition, a tox-
icological screening of alcohol, pharmaceutical drugs and
illicit drugs are performed in most of these cases. How-
ever, post-mortem degradation [21] and redistribution
[22,23] may significantly alter blood drug levels after
death. The concentrations can vary between sampling
sites, and may change over time, particularly at high ambi-
ent temperatures. To reduce these errors that affect some
drugs more than others, a standardised procedure for
sampling, handling and analysis of toxicological samples
was introduced at all forensic medicine departments in
Sweden in 1990.
One limitation of the present study is its retrospective
design. Despite scrutinising the medico-legal files, medi-
cal charts, police reports and additional sources of infor-
mation, it is impossible to obtain all relevant information
in each case; hence the number of drug poisonings might
have been underestimated. Moreover, the number of fatal
poisonings observed in the study is limited. On the other
hand, this study has several strengths compared with pre-
vious studies. The population based approach includes a
random selection of all deceased subjects in the study
area. In 99% of the cases, it was possible to follow the gen-
eral health and drug histories over a relevant period of
time prior to death by consulting various sources. Further-
more, the application of a multidisciplinary approach
during evaluation of the suspected drug poisonings
reduces the risk of misclassification. Cases with a more
likely alternative explanation for the death, with uncer-
tainties or inconsistencies related to the information
found were excluded as suspected drug poisonings. Using
this conservative approach, consensus was achieved for all
cases included.
Benzodiazepines, antihistamines and opioid analgesics
were most commonly associated with fatal poisonings in
this study but the numbers in each group were small. The
substances detected may reflect their inherent toxicity, but
also their sales and overall use [24,25], which vary
between geographical areas [26]. The present study veri-
fies that drug groups commonly involved in fatal drug
poisonings include analgesics, antidepressants and seda-
tives in Europe. The same pattern has been seen in North
America, but is not necessarily present in other areas of
the world [1,7].
Conclusion
In conclusion, fatal drug poisonings are a relatively com-
mon cause of death in Sweden. By using multiple sources
of information when investigating the proportion of fatal
poisonings in a population, more accurate estimates may
be obtained.
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